Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SCYX Stock Forecast 2026-2027
$0.65
Current Price
$27.42M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SCYX Price Targets
+511.6%
To High Target of $4.00
+511.6%
To Median Target of $4.00
+358.7%
To Low Target of $3.00
SCYX Price Momentum
-3.0%
1 Week Change
+1.6%
1 Month Change
-44.4%
1 Year Change
+3.2%
Year-to-Date Change
-50.1%
From 52W High of $1.31
+15.8%
From 52W Low of $0.57
📊 TOP ANALYST CALLS
Did SCYX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if SCYNEXIS is one of their latest high-conviction picks.
Latest SCYX Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, SCYX has a bullish consensus with a median price target of $4.00 (ranging from $3.00 to $4.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.65, the median forecast implies a 511.6% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason McCarthy at Maxim Group, projecting a 511.6% upside. Conversely, the most conservative target is provided by Vamil Divan at Guggenheim, suggesting a 358.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SCYX Analyst Ratings
3
Buy
0
Hold
0
Sell
SCYX Price Target Range
Low
$3.00
Average
$4.00
High
$4.00
Current: $0.65
Latest SCYX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SCYX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 28, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $3.00 |
| Apr 1, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Aug 15, 2023 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $15.00 |
| Apr 3, 2023 | Ladenburg Thalmann | Michael Higgins | Buy | Reiterates | $15.00 |
| Apr 3, 2023 | Guggenheim | Vamil Divan | Buy | Maintains | $9.00 |
| Mar 1, 2023 | Guggenheim | Vamil Divan | Buy | Initiates | $8.00 |
| Oct 21, 2022 | Brookline Capital | Kemp Dolliver | Buy | Assumes | $8.00 |
| May 13, 2022 | HC Wainwright & Co. | Oren Livnat | Buy | Maintains | $8.00 |
| Mar 31, 2022 | HC Wainwright & Co. | Oren Livnat | Buy | Maintains | $14.00 |
| Jun 7, 2021 | Aegis Capital | Nathan Weinstein | Buy | Maintains | $35.00 |
| Apr 12, 2021 | Aegis Capital | Nathan Weinstein | Buy | Maintains | $40.00 |
| Jan 22, 2021 | Guggenheim | Buy | Initiates | $N/A | |
| Jan 6, 2021 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Dec 28, 2020 | HC Wainwright & Co. | Buy | Reiterates | $20.00 | |
| Nov 25, 2020 | H.C. Wainwright | Buy | Initiates | $N/A | |
| Nov 25, 2020 | Needham | Buy | Initiates | $N/A | |
| Nov 25, 2020 | JMP Securities | Market Perform | Initiates | $N/A | |
| Nov 25, 2020 | Guggenheim | Buy | Initiates | $N/A | |
| Nov 25, 2020 | WBB Securities | Strong Buy | Upgrade | $N/A | |
| Nov 25, 2020 | Canaccord Genuity | Buy | Initiates | $N/A |
Scynexis Inc. (SCYX) Competitors
The following stocks are similar to SCYNEXIS based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Scynexis Inc. (SCYX) Financial Data
Scynexis Inc. has a market capitalization of $27.42M with a P/E ratio of 0.9x. The company generates $2.93M in trailing twelve-month revenue with a 100.0% profit margin.
Revenue growth is -49.4% quarter-over-quarter, while maintaining an operating margin of -2,516.5% and return on equity of -53.3%.
Valuation Metrics
Market Cap
$27.42M
Enterprise Value
$-8,131,708
P/E Ratio
0.9x
PEG Ratio
0.0x
Price/Sales
9.4x
Growth & Margins
Revenue Growth (YoY)
-49.4%
Gross Margin
N/A
Operating Margin
-2,516.5%
Net Margin
+100.0%
EPS Growth
-49.4%
Financial Health
Cash/Price Ratio
+138.2%
Current Ratio
5.8x
Debt/Equity
6.3x
ROE
-53.3%
ROA
-28.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Scynexis Inc. (SCYX) Business Model
About Scynexis Inc.
What They Do
Develops innovative anti-infective therapies.
Business Model
The company focuses on creating and commercializing antifungal treatments, with its leading product being ibrexafungerp, aimed at serious and hard-to-treat fungal infections. It generates revenue through the sale of these therapeutic products and potentially through partnerships in research and development within the healthcare sector.
Additional Information
Scynexis plays a vital role in addressing unmet medical needs in infectious diseases, particularly in combating resistant pathogens. The company is headquartered in the United States and is dedicated to advancing healthcare solutions that improve patient outcomes.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
28
CEO
Dr. David Gonzalez Angulo M.D.
Country
United States
IPO Year
2014
Website
www.scynexis.comScynexis Inc. (SCYX) Latest News & Analysis
Latest News
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
24 days ago
Quick Summary
SCYNEXIS, Inc. has received a 180-day extension from Nasdaq to meet the minimum bid price requirement under Listing Rule 5550(a)(2).
Why It Matters
SCYNEXIS's extension to meet Nasdaq's minimum bid price requirement indicates potential financial instability, which may affect stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
SCYNEXIS, Inc. has transferred the New Drug Application for BREXAFEMME (ibrexafungerp) to GSK, indicating a shift in its drug development strategy.
Why It Matters
The transfer of BREXAFEMME's NDA to GSK signals potential strategic partnerships and revenue shifts, impacting SCYNEXIS's financial outlook and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
SCYNEXIS, Inc. (NASDAQ: SCYX) reported its Q3 financial results for 2025, focusing on innovative medicines for difficult-to-treat and drug-resistant infections.
Why It Matters
SCYNEXIS's financial results can indicate its market performance and potential for growth in the biotech sector, impacting stock valuation and investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
3 months ago
Quick Summary
SCYNEXIS, Inc. (NASDAQ: SCYX) will receive $22 million from GlaxoSmithKline to resolve a disagreement over the Phase 3 MARIO study, plus $2.3 million for wind-down activities.
Why It Matters
SCYNEXIS's $22 million payment from GSK indicates financial support despite halted study progress, impacting cash flow and investor confidence in its R&D viability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
SCYNEXIS, Inc. (NASDAQ: SCYX) will present data on its second-generation fungicidal drug candidate, SCY-247, at the TIMM-12 conference in Bilbao, Spain, from September 19-22, 2025.
Why It Matters
SCYNEXIS's upcoming presentations on SCY-247 may signal advancements in addressing drug-resistant infections, potentially impacting its market position and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
SCYNEXIS, Inc. (NASDAQ: SCYX) reported its Q2 2025 financial results on August 13, highlighting its focus on innovative treatments for drug-resistant infections.
Why It Matters
SCYNEXIS's financial results may indicate its growth potential and market performance, influencing stock value and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SCYX Stock
What is Scynexis Inc.'s (SCYX) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Scynexis Inc. (SCYX) has a median price target of $4.00. The highest price target is $4.00 and the lowest is $3.00.
Is SCYX stock a good investment in 2026?
According to current analyst ratings, SCYX has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SCYX stock?
Wall Street analysts predict SCYX stock could reach $4.00 in the next 12 months. This represents a 511.6% increase from the current price of $0.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Scynexis Inc.'s business model?
The company focuses on creating and commercializing antifungal treatments, with its leading product being ibrexafungerp, aimed at serious and hard-to-treat fungal infections. It generates revenue through the sale of these therapeutic products and potentially through partnerships in research and development within the healthcare sector.
What is the highest forecasted price for SCYX Scynexis Inc.?
The highest price target for SCYX is $4.00 from Jason McCarthy at Maxim Group, which represents a 511.6% increase from the current price of $0.65.
What is the lowest forecasted price for SCYX Scynexis Inc.?
The lowest price target for SCYX is $3.00 from Vamil Divan at Guggenheim, which represents a 358.7% increase from the current price of $0.65.
What is the overall SCYX consensus from analysts for Scynexis Inc.?
The overall analyst consensus for SCYX is bullish. Out of 8 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are SCYX stock price projections?
Stock price projections, including those for Scynexis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 4:15 AM UTC